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The dichotomy of NMDA receptor signalling
Sofia Papadia and Giles E. Hardingham*
Centre for Neuroscience Research, University of Edinburgh, Hugh Robson Building, Edinburgh
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Abstract
The NMDA subtype of ionotropic glutamate receptors plays a Jekyll and Hyde role in the
mammalian central nervous system. In pathological scenarios such as ischemia, Ca2+ influx
through the NMDA receptor is a key mediator of cell death. However, physiological levels of
NMDA receptor activity can promote neuronal survival and resistance to trauma, and play
important roles in synaptic plasticity and transmission. This dichotomy may explain the poor
tolerance and efficacy of NMDA receptor antagonists in clinical trials for excitotoxic trauma.
There is a growing understanding of the signalling events that mediate the opposing effects of
NMDA receptor activity, and the factors that determine whether an episode of NMDA receptor
activity will promote survival or death. This knowledge may lead to therapeutic strategies that
enable the selective blockade of pro-death signalling cassettes, while sparing physiological
signalling to survival and plasticity.
1. Introduction
NMDARs (N-methyl-D-aspartate (NMDA) receptors) are cationotropic receptors gated by
the neurotransmitter glutamate. They play a central role in synaptic transmission and in
mediating synaptic plasticity, learning and memory. NMDARs are also present in other cell
types such as oligodendrocytes (Karadottir and others 2005), osteoclasts (Szczesniak and
others 2005) and lymphocytes (Tuneva and others 2003) where their function is not well
understood. Structurally they are heterotetramers, typically containing two glycine-binding
NR1 subunits and two glutamate-binding NR2 subunits. The NR1 subunit is essential for a
functional NMDAR, and has several splice variants that can influence the properties of the
channel. In addition, NMDAR variety is provided by the four different NR2 subunits
(NR2A-D) as well as two NR3 genes (NR3A and NR3B) which can take the place of NR2.
The most widely expressed NMDARs contain the obligate subunit NR1 plus either NR2B or
NR2A or a mixture of the two. NR2B (and NR2D) is expressed at high levels in early
developmental stages which decline post-natally, while NR2A and NR2C expression levels
increase (Kohr 2006). In adults, NR2A is ubiquitously expressed in the brain, NR2B is
mostly restricted to the forebrain, NR2C to the cerebellum and NR2D is expressed in small
numbers of cells in selected brain regions. However, NR2A and NR2B exist concurrently in
the same brain region and participate in the formation of a heterotrimeric NR1/NR2A/NR2B
functional NMDARs (Waxman and Lynch 2005).
The NMDAR channel pore is blocked in a voltage-dependent manner by Mg2+. Release of
glutamate, the main excitatory neurotransmitter in the mammalian CNS (central nervous
system), causes Na+ influx through AMPA receptors in the postsynaptic cell, resulting in
partial membrane depolarisation sufficient to lift the Mg2+ block. The activated NMDAR is
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permeable to Na+ but, crucially, also to Ca2+. This Ca2+ mediates most of the physiological
effects of NMDAR activity.
At the synapse, the NMDAR is linked to a large multi-protein complex via the cytoplasmic
C-termini of NR1 and NR2 subunits (Collins and others 2006). This complex facilitates
localisation of the receptor in specific areas, such as the postsynaptic density- PSD, and
facilitates connection to a variety of downstream signalling molecules through which many
NMDAR activity downstream effects are mediated (Waxman and Lynch 2005). The
extreme C-termini of NR2 subunits link to a group of proteins called MAGUKs (Membrane-
associated Guanylate Kinase) which include PSD-95, SAP-102 (synapse-associated protein)
and PSD-93. These proteins contain several PDZ protein interaction domains through which
other proteins are connected. This highly organised structure facilitates signal coupling, by
bringing together cytoplasmic signal-transducing enzymes and cell-surface receptors.
Moreover, it can bring Ca2+ dependent signalling molecules into close proximity with the
site of Ca2+ entry at NMDAR. For example, nNOS, in interacting with PSD-95, is brought
close to the NMDAR and can thus be efficiently activated by NMDAR-mediated Ca2+
influx (Aarts and others 2002).
NMDARs are essential mediators of synaptic plasticity and also mediate aspects of
development and synaptic transmission (Aamodt and Constantine-Paton 1999; Bliss and
Collingridge 1993). However, when excessively activated, NMDARs cause cell death in
many neuropathological scenarios (Lipton and Rosenberg 1994). During an ischemic
episode, extracellular glutamate builds up due to synaptic release and impaired/reversed
uptake mechanisms (Camacho and Massieu 2006; Rossi and others 2000) resulting in
overactivation of NMDARs (Choi 1988). The destructive effects of excessive NMDAR
activity are in contrast to the recent findings that survival of several neuronal types is
dependent on physiological synaptic NMDAR activity (Hardingham and Bading 2003;
Ikonomidou and Turski 2002a). Thus, responses of neurons to glutamate or NMDA follow a
bell-shaped curve: both too much and too little NMDAR activity is potentially harmful
(Lipton and Nakanishi 1999).
2. Failed clinical trials for stroke with NMDA receptor antagonists
Despite an overwhelming body of evidence from animal studies implicating NMDAR
activity in neuronal loss following ischemia, the many clinical trials of different NMDAR
antagonists for stroke have failed due to poor tolerance and efficacy (Ikonomidou and Turski
2002a; Muir 2006). Aptiganel, one of the final generation of antagonists, is a case-in-point.
Clinical trials were suspended due to lack of efficacy and emerging data that high-dose
Aptiganel patients exhibited worse neurological improvement and higher mortality
compared to placebo (Albers and others 2001). Lack of efficacy was observed despite using
doses that caused side-effects such as hypertension, as well as CNS-adverse events such as
sedation, confusion, headache and psychosis (Dyker and others 1999). The important role of
the NMDAR in normal CNS functioning may mean that for any antagonist the maximal
tolerated dose is lower than the minimum therapeutically effective dose. Moreover, the
growing body of evidence that physiological synaptic NMDAR activity exerts a
neuroprotective effect has led to suggestions that it may play a role in promoting recovery
and preventing delayed neuronal loss in the penumbra (Albers and others 2001; Ikonomidou
and Turski 2002a). Indeed, preconditioning type events are likely to be initiated in the
marginal area in the penumbra, and since preconditioning is NMDAR dependent (Grabb and
Choi 1999), blockade may be undesirable in this region. Thus, global NMDAR antagonists
may block NMDAR-activated pro-survival signals triggered in response to an ischemic
challenge, and actually delay recovery in some areas. This dichotomy of NMDAR signalling
(Hardingham and Bading 2003) means that any anti-excitotoxic strategy that interferes with
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NMDAR signalling should be assessed to determine its effects on NMDAR pro-survival
signalling. This will require a thorough understanding of the nature of both survival and
death pathways triggered by the NMDAR. In this review we will focus on survival and
death signalling through the NMDA receptor, exploring newly emerged concepts and the
molecules involved.
3. Pro-survival signalling from the NMDAR
In contrast to the adverse effects of excessive NMDAR activity, physiological levels of
synaptic NMDAR activity are essential for neuronal survival, since activity blockade was
shown to have deleterious effects. Blockade of NMDAR activity in vivo caused a decrease
in the number of healthy cells, increased density of pyknotic cells and severe deterioration of
the dentate gyrus morphology in first week postnatal rat pups (Gould and others 1994).
Elimination of NMDA receptor activity in vivo causes widespread apoptosis and enhances
trauma-induced injury in developing neurons (Adams and others 2004; Gould and others
1994; Ikonomidou and others 1999; Monti and Contestabile 2000; Pohl and others 1999). In
the adult CNS, NMDAR blockade exacerbates neuronal loss when applied after traumatic
brain injury and during ongoing neurodegeneration (Ikonomidou and others 2000), and
prevents the survival of newborn neurons in the adult dentate gyrus (Tashiro and others
2006).
NMDAR signalling to survival has been recapitulated in vitro in neuronal cultures
(Hardingham and Bading 2003; Hetman and Kharebava 2006), allowing scientists to study
the underlying signalling events. Network disinhibition using the GABAa receptor
antagonist bicuculline enabled selective studies of synaptic NMDAR activity signalling
(Hardingham and others 2001b), as opposed to using the unphysiological bath application of
glutamate which would activate synaptic and extrasynaptic NMDARs. Bicuculline blockade
of the tonic inhibition mediated by GABAergic interneurons promotes action potential
bursting which are associated with synaptic NMDAR-dependent Ca2+ transients
(Hardingham and others 2002).
Pro-survival signalling from the NMDA receptor can involve posttranslational modifications
of proteins or indeed de novo gene expression. Different signals may have varying
importance under different circumstances (Papadia and others 2005). We outline below
examples of pro-survival pathways triggered by synaptic NMDAR activity (see also Fig. 1),
and the pro-survival events that they mediate.
3a. The PI3K-Akt pathway
The PI3K (phosphoinositide-3-kinase) - Akt kinase cascade is a key signalling pathway
responsible for pro-survival effects of NMDAR activity (Lafon-Cazal and others 2002;
Papadia and others 2005). It is strongly activated by NMDAR in many neuronal types, but
not in all (Hetman and Kharebava 2006). Briefly, in response to extracellular stimuli, PI3K,
which can be activated in a Ca2+-dependent manner by Ca2+/calmodulin (Joyal and others
1997), catalyses the phosphorylation of the lipid PIP2 (phosphatidylinositol 4,5-
biphosphate) to PIP3 (phosphatidylinositol 3,4,5-triphosphate) in the membrane. The kinase
PDK1 (phosphoinositide-dependent protein kinase) (Alessi and others 1997) as well as its
substrate Akt/PKB (Protein Kinase B) are recruited to the membrane via their interactions
with PIP3 through their pleckstrin homology (PH) domains. PDK1, along with PDK2
(which is possibly rictor-mTOR- (Sarbassov and others 2005)) then phosphorylates and
activates Akt. Akt promotes cell survival and growth via phosphorylation and activation or
inactivation of its many targets: Akt phosphorylates and inactivates GSK3β (Glycogen
synthase kinase-3 beta; (Cross and others 1995)), an event that also contributes to NMDAR
signalling to neuroprotection (Soriano and others 2006). In the context of neurotrophic
Papadia and Hardingham Page 3
Neuroscientist. Author manuscript; available in PMC 2010 March 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
factor and growth factor signalling Akt triggers phosphorylation of the FOXO (forkhead box
O) subfamily of forkhead transcription factors, promoting translocation from the nucleus to
the cytoplasm (Brunet and others 1999). FOXOs control the expression of pro-death genes
such as Fas ligand (Brunet and others 1999) and Bim (Gilley and others 2003), and these are
down-regulated by Akt activation. NMDAR signalling to Akt-dependent FOXO export has
also been observed in the context of NMDAR signalling (Soriano and others 2006). Akt also
inactivates the pro-apoptotic Bcl-2 family member BAD (Bcl2/Bcl-XL-antagonist causing
cell death) by phosphorylation, thus stopping its interaction with and blockade of the pro-
survival Bcl-2 family members Bcl-2 and Bcl-XL (Downward 1999). The JNK/p38 activator
ASK1 can also be inhibited by Akt phosphorylation (Kim and others 2001) and p53
transcriptional activity is suppressed by Akt, leading to reduction of Bax expression and of
neuronal death (Yamaguchi and others 2001).
3b. CREB (cAMP response element-binding protein)
A key mediator of activity-dependent gene expression is the transcription factor CREB,
which binds to the cAMP response element (CRE) (Lonze and Ginty 2002). CRE-dependent
gene expression is strongly induced by synaptic NMDAR activity (Hardingham and others
2002). Ca2+ influx through the synaptic NMDAR activates the Ras/ERK pathway in the
cytoplasm and the nuclear Ca2+/calmodulin dependent protein kinases, principally
CaMKIV. CaMKIV mediates fast CREB phosphorylation at Ser133, whereas the ERK1/2
pathway promotes CREB phosphorylation in a slower, more long lasting manner
(Hardingham and others 2001a; Wu and others 2001). Ser133 phosphorylation of CREB is
necessary to recruit CBP (CREB-binding protein), a transcriptional cofactor, to CREB. The
transactivation potential of CBP is itself positively regulated by NMDAR activity
(Hardingham and others 1999) by a mechanism involving its phosphorylation on Ser301 by
CaMKIV (Impey and others 2002). Gene expression mediated by CREB can also be
mediated by another family of CREB co-activators, the TORCs (Transducers of Regulated
CREB activity, (Kovacs and others 2007; Screaton and others 2004) and references therein).
TORC2 translocates to the nucleus as a result of the synergistic action of Ca2+ and cAMP
signalling, through calcineurin-mediated TORC2 dephosphorylation and cAMP-mediated
inhibition of the TORC2 kinase SIK2, respectively (Screaton and others 2004). In
hippocampal neurons TORC1, which is expressed more abundantly than TORC2, senses the
coincidence of Ca2+ and cAMP signalling and converges this dual signalling to target gene
expression by translocating to the nucleus and potently coactivating CREB (Kovacs and
others 2007).
The potential of CREB family-regulated gene products to promote neuronal survival was
first demonstrated in the context of neurotrophin signalling (Bonni and others 1999; Riccio
and others 1999) and exogenous overexpression (Walton and others 1999). In addition,
studies of mice where CREB and/or CREB family members have been deleted also point to
a pro-survival role for CREB: CREB null mice exhibit considerable death of dorsal root
ganglion neurons in vivo, and sympathetic neurons in vitro (Lonze and others 2002). Mice
lacking CREB (and that also lack CREM-another CREB family member) in the CNS during
development show extensive neuronal apoptosis (Mantamadiotis and others 2002). Postnatal
disruption of the CREB gene (in CREM null mice) results in progressive neurodegeneration
in the hippocampus and dorsolateral striatum (Mantamadiotis and others 2002).
CREB-dependent gene expression is causally linked to the long-lasting phase of activity-
dependent neuroprotection against apoptotic insults (Papadia and others 2005). This long-
lasting phase is dependent on nuclear Ca2+/calmodulin signalling (Papadia and others 2005),
consistent with the known requirement for nuclear Ca2+ in CREB activation via CaMKIV
(Deisseroth and others 1998; Hardingham and others 2001b; Hardingham and others 1997;
Limback-Stokin and others 2004). Activity-dependent CRE activation in developing CNS
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neurons also protects against excitotoxic trauma (Lee and others 2005) which would
otherwise result in rapid cell death resembling necrosis. Expression of the inhibitory CREB
family member, ICER increases in neurons in response to apoptotic and excitotoxic insults
and can promote neuronal death (Jaworski and others 2003). Thus, CREB activation by
NMDAR signalling may be important in antagonizing the CREB-inhibiting effects of ICER
accumulation.
The importance of NMDAR signalling to CREB in promoting survival in vivo is not as well
established. Activation of CREB in response to transient ischemic episodes is proposed to
contribute to the establishment of ischemic tolerance or preconditioning and may well be
mediated by NMDAR activation (Mabuchi and others 2001). Interestingly, resistance to
hypoxic/ischemic death in different neuronal populations correlates positively with an
ability to sustain active (phosphorylated) CREB (Walton and Dragunow 2000): in neurons
destined to die CREB is only transiently phosphorylated (Walton and Dragunow 2000).
The identity of the CRE-regulated gene(s) responsible for long lasting protection against
apoptosis is beginning to be understood. Genome-wide profiling studies have identified a
large number of CREB target genes, although only a subset of these are induced by CREB-
activating stimuli (Impey and others 2004; Mayr and Montminy 2001; Zhang and others
2005). Furthermore, the identity of the genes within the subset is cell-type specific and may
be stimulus-specific, so is hard to predict in any particular scenario.
A recent study identified two genes that contribute to synaptic NMDAR-dependent
neuroprotection (Zhang and others 2007): Btg2, a potentially anti-apoptotic CREB target
gene, and Bcl6, a transcriptional repressor implicated in suppression of p53, also potentially
a CREB target. Both Btg2 and Bcl6 genes confer neuroprotection in the face of apoptotic
stimuli like trophic deprivation and staurosporine treatment, and siRNA-mediated
knockdown demonstrated that their induction was also necessary for synaptic NMDAR-
mediated neuroprotection.
Another CRE-regulated candidate is the pro-survival neurotrophin BDNF (brain-derived
neurotrophic factor), which is upregulated by NDMAR activity (Hardingham and others
2002) and is known to promote neuronal survival (Shieh and others 1998; Tao and others
1998) (Hetman and Kharebava 2006). NMDAR blockade in vivo reduces BDNF mRNA
expression and in vitro supplementation of neurons with BDNF can rescue them from
NMDAR antagonist-caused neuronal death (Hansen and others 2004). Upregulation of other
known CREB targets involved in metabolism and respiration (e.g. Cytochrome c), responses
to oxidative stress (e.g. Sod2-superoxide dismutase 2) or in inhibiting apoptosis (e.g. Bcl-2)
(Riccio and others 1999) are additional potential ways in which CREB can promote survival
and resistance to trauma. It is possible that different CRE-regulated genes are responsible for
neuroprotection against different types of insult (e.g. apoptotic-like, excitotoxic/necrotic-
like, oxidative stress).
4. NMDAR-mediated cell death
Pathological activation of NMDARs is a major cause of neuronal death following acute
excitotoxic trauma such as brain ischaemia, hypoxia and mechanical trauma (Arundine and
Tymianski 2004). Chronic neurodegenerative diseases may also be associated with
excessive NMDAR activation (Lipton 2006; Lipton and Rosenberg 1994). Neuronal cultures
respond to high levels of NMDAR activity, induced by bath application of glutamate or
NMDA, by undergoing delayed Ca2+ deregulation that precedes and predicts necrotic cell
death (Hartley and others 1993) and references therein). Several mechanisms are implicated
in cell death triggered by Ca2+ influx through the NMDAR (see below and also Fig. 1).
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Mitochondrial dysfunction caused by excessive Ca2+ uptake by the mitochondria through
the potential-driven uniporter (Stout and others 1998) is one mechanism. The mitochondrial
membrane gets depolarised due to this uptake, which inhibits ATP production, and can even
cause depletion of cytosolic ATP due to reversal of the mitochondrial ATPase. This loss of
ATP further limits the ability of the neuron to regulate intracellular Ca2+ levels.
Furthermore, mitochondrial Ca2+ uptake can promote ROS production (Nicholls 2004) and
also release of cytochrome c, necessary for the formation of the apoptosome and subsequent
activation of caspases, leading to apoptosis.
In addition to causing mitochondrial dysfunction, toxic levels of NMDAR activation cause
Ca2+ efflux to be impaired (Bano and others 2005; Pottorf and others 2006). In neurons Ca2+
exit from the cell is achieved through the plasma membrane Ca2+ ATPase pump (PMCA)
and Na+/Ca2+ exchangers (NCXs). Calpains, Ca2+-dependent proteases, are activated by the
excessive NMDAR-mediated Ca2+ influx and cleave a major isoform of the plasma
membrane Na+/Ca2+ exchanger (NCX3) impairing its function in cerebellar granule neurons
(CGNs) (Bano and others 2005). Inhibition of calpains or overexpression of a functional
NCX isoform prevented Ca2+ overload while siRNA knockdown of NCX3 exacerbated it
(Bano and others 2005). The PMCA, which would utilise the energy from ATP hydrolysis to
transport Ca2+ across the plasma membrane, is inactivated by excitotoxic insults via
mechanisms attributed to both caspases (Schwab and others 2002) and calpains (Pottorf and
others 2006).
NMDAR activity-regulated overactivation of the Ca2+-dependent nNOS (neuronal nitric
oxide synthase) also has toxic downstream responses, including mitochondrial dysfunction,
p38 mitogen-activated protein kinase signalling and TRPM (transient receptor potential
melastatin) channel activation. nNOS is bound by its N-terminal PDZ domain to the post-
synaptic density protein PSD95, which brings it in the proximity of the synaptic NMDAR
that is also bound to PSD95 via the C-terminal tail of its NR2 subunit. nNOS activation
leads to Nitric Oxide (NO) production, which in excess can be toxic both on its own and
when combined with other reactive oxygen species (ROS) such as superoxide to form
ONOO- (peroxynitrite). Both NO and ONOO− can damage cellular components, inhibit
mitochondrial respiratory chain enzymes and promote mitochondrial depolarisation
(Arundine and Tymianski 2004). Another important target of NMDAR signalling to NO
production in excitotoxicty is the cation channel TRPM7 (Aarts and others 2003). NMDAR-
dependent Ca2+ influx triggers both NO production via nNOS activation and superoxide
production via mitochondrial Ca2+ uptake, which combine to form ONOO−, an activator of
TRPM7. Since TRPM7 itself passes Ca2+, this results in a positive feedback loop.
Stress-activated protein kinases (SAPKs) are another class of signalling molecules that
mediate NMDAR-dependent cell death. In CGNs, NMDAR-dependent excitotoxic death
relies upon p38 activation, leading to caspase-independent cell death (Cao and others 2004).
In cortical neurons another SAPK family, the c-Jun N-terminal kinases (JNKs) mediated
NMDAR-dependent cell death in cortical neurons in vitro and in vivo (Borsello and others
2003). New components of the excitotoxic cell death pathway are emerging; Rho, a member
of the Rho-family of GTPases, was recently found to link glutamate-induced Ca2+ elevation
to p38α-dependent excitotoxic neuronal death (Semenova and others 2007).
5. What determines if an episode of NMDAR activity is neuroprotective or
excitotoxic?
As outlined above, there is a multitude of ways in which NMDAR-dependent Ca2+influx
can convey the signal downstream to either confer neuroprotection or to trigger programmes
of cell death. A key issue, potentially relevant for designing clinically tolerated drugs against
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neurodegenerative conditions caused by excitotoxicity, is how the distinction between what
pathway will be followed is made and what factors affect this. A number of possibilities are
presented here.
5a. Stimulus intensity
The magnitude of activation, be it intensity or duration, is very important in determining the
nature of the response to an episode of NMDAR activity. The classical bell-shaped curve
model of the neuronal response to NMDA or glutamate contends that intermediate,
physiological NMDAR activity levels are necessary for neuroprotection whereas too low or
too high pathological NMDAR activity promotes cell death. This implies that the effectors
of the pro-survival Ca2+ signalling have a higher affinity (or considerably lower
requirements for Ca2+) than the Ca2+ effectors of death. Therefore the Ca2+ concentration
threshold for activating pro-survival signalling by PI3K, ERK1/2 and CaMKIV must be
lower than that necessary to trigger toxic levels of calpain activation, mitochondrial Ca2+
uptake or NO production. The key Ca2+ -dependent components of the survival pathways
are in the main activated not by Ca2+ directly, but by Ca2+/Calmodulin. Calmodulin is a
ubiquitous Ca2+ binding protein which changes conformation when it binds to Ca. Ca2+/
Calmodulin then activates a number of downstream signals, including CaMKIV, PI3K and
upstream activators of ERK1/2. As a physiological sensor of elevated Ca2+ levels,
calmodulin is designed to be activated by relatively modest increases in Ca2+. In contrast,
central mediators of NMDAR-dependent cell death, calpains, are not Ca2+/Calmodulin
dependent but are activated by Ca2+ directly, and require higher levels to be fully induced
(Tompa and others 1996). The same can be said of the mitochondrial uniporter, which
senses Ca2+ directly and is fully activated only by high concentrations (Nicholls 2004).
Consistent with this, when increasing doses of NMDA are applied to neurons, only the
higher, toxic doses evoke sustained loss of mitochondrial membrane potential and increases
in mitochondrial Ca2+ (Soriano and others 2006). Another Ca2+-dependent promoter of
neuronal death, nNOS, is Ca2+/Calmodulin-dependent and indeed plays important roles in
non-pathological signalling processes such as synaptic plasticity. However, nNOS is also
regulated by phosphorylation, and a recent study showed that, in contrast to non toxic
stimuli, high levels of glutamate fail to trigger an inhibitory phosphorylation event that
ensures that nNOS activation is transient (Rameau and others 2007). Thus, nNOS becomes
excessively active and contributes to excitotoxic cell death (Rameau and others 2007).
5b. Location of the receptor
Aside from stimulus intensity, the location of the NMDAR may also profoundly affect the
signals that emanate from the NMDAR. Developing neurons have sizeable pools of
NMDARs at extrasynaptic, as well as synaptic locations, which signal very differently. Ca2+
influx dependent on intense synaptic NMDAR activation is well tolerated by cells whereas
activation of extrasynaptic NMDARs, either on their own or in the presence of synaptic
NMDAR activation, causes a loss of mitochondrial membrane potential and cell death
(Hardingham and others 2002).
Differential synaptic vs extrasynaptic NMDAR effects also extend to other signal pathways.
While synaptic NMDAR activity strongly induces CREB-dependent gene expression,
extrasynaptic NMDARs are coupled to a CREB shut-off pathway that causes CREB
dephosphorylation of its activator site (serine 133)(Hardingham and others 2002). The
developmentally regulated mechanism of this is discussed elsewhere (Hardingham and
Bading 2002; Sala and others 2000). The extrasynaptic NMDAR activity-dependent
dephosphorylation of CREB is generally dominant over CREB-activating signals
(Hardingham and others 2002), possibly by activating a CREB phosphatase such as PP1
(protein phosphatase 1). In neurons exposed to low protecting doses of NMDA, synaptic
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NMDAR signalling is able to dominate because synaptic NMDARs are preferentially
activated due to the NMDA causing a dramatic increase in action potential firing (Soriano
and others 2006). This enhanced firing mediates the NMDA-induced pro-survival signalling
to Akt, ERK1/2 and CREB. In contrast, higher, toxic doses of NMDA strongly suppress
firing rates and hence do not favour synaptic NMDAR activation (Soriano and others 2006).
In addition to signalling to CREB, it has also been shown that there is opposing regulation of
the ERK1/2 pathway by synaptic and extrasynaptic NMDARs in hippocampal neurons:
Synaptic NMDARs activate the ERK pathway whereas extrasynaptic NMDARs evoke ERK
inactivation (Ivanov and others 2006).
A recent study involving genome-wide expression analysis has extended our understanding
of synaptic vs. extrasynaptic signalling (Zhang and others 2007). While synaptic NMDARs
activated a number of pro-survival genes (including the aforementioned Btg2 and Bcl6),
extrasynaptic NMDARs failed to do this, and in fact activated expression of a gene Clca1
which kills neurons. It will be of interest to know whether Clca1 is activated in vivo during
excitotoxic trauma, and whether it represents a potential therapeutic target.
Chronic exposure of neurons to glutamate and activation of extrasynaptic NMDARs is
unlikely to occur under normal physiological conditions. However, it may occur under
pathological conditions such as brain injury, or during hypoxic/ischemic insults where
glutamate transporters operate in reverse (Rossi and others 2000) thereby pumping
glutamate out of the cells into the extracellular medium, building up in the restricted
extracellular space. Indeed, exposing hippocampal neurons to oxygen-glucose-free
conditions causes a NMDAR-dependent decay of CREB phosphorylation (Hardingham and
others 2002). This is consistent with the observation that CREB dephosphorylation has been
observed in in vivo stroke conditions (Tanaka and others 1999; Walton and Dragunow
2000). Given the role of CREB in controlling several pro-survival genes, this shut-off may
contribute to the slowly progressing apoptotic death of neurons (in response to excitotoxic
trauma) that are exposed to toxic levels of glutamate that are insufficient to cause immediate
necrotic cell death (Dirnagl and others 1999; Hossmann 1994; Lee and others 1999). The
dominant action of the shut-off signal means that any CREB activating ligand present (such
as a neurotrophin) would be rendered impotent.
The molecular basis for the apparent differences in synaptic/extrasynaptic NMDAR
signalling could be due to differences in the composition of the NMDAR signalling
complexes as opposed to the location of the receptors per se, though these potential
differences await study. Molecules involved in the CREB shut-off mechanism or in the
coupling to mitochondrial Ca2+ uptake may directly interact with extrasynaptic NMDARs.
They may interact less well with synaptic NMDARs, due to shielding by the post-synaptic
density or differences in receptor subunit composition. While extrasynaptic NMDARs are
preferentially enriched with NR2B-containing NMDARs, there is little evidence that
differences in subunit composition are dramatic enough to explain the effects observed.
However, a recent study has contended that NR2B-containing NMDARs tend to promote
neuronal death, irrespective of location (synaptic or extrasynaptic) while NR2A-containing
NMDARs promote survival (Liu and others 2007). The investigation of subunit-specific
differences in NMDAR signalling is hampered by the lack of a NR2A-specific antagonist
that is sufficiently selective to discriminate in the physiological scenario of trans-synaptic
stimulation (Frizelle and others 2006; Neyton and Paoletti 2006). The antagonist NVP-
AAM077 has some selectivity for NR2A-containing NMDARs but the difference in the
equilibrium constants is not sufficient to discriminate between NR2A-containing or NR2B-
containing NMDA receptors being trans-synaptically activated (Frizelle and others 2006).
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6. Clinical implications and concluding remarks
The pro-survival role of synaptic NMDARs under physiological conditions and especially
during CNS development, points to the potential dangers of NMDAR antagonism during
this period in humans (Olney and others 2002). Several paediatric/obstetric anaesthetics and
anticonvulsants reduce NMDAR activity directly or indirectly; in addition, in utero exposure
to NMDAR-antagonistic recreational drugs such as phencyclidine, ketamine and ethanol
pose very real risks (Olney and others 2002).
Moreover, the capability of NMDAR signalling to promote both survival and cell death
under different circumstances, highlights the problem of designing anti-excitotoxic
therapeutic drugs without causing undesirable adverse effects. As outlined earlier, trials of
NMDAR antagonists for treating excitotoxic trauma such as stroke have failed in the past
due to poor tolerance and efficiency (Ikonomidou and Turski 2002b), likely caused by
inhibition of physiological NMDAR-mediated processes such as pro-survival signalling and
plasticity. It is becoming more widely accepted that the way forward is to block the
excitotoxic consequences of NMDAR activation while preserving pro-survival signals, and
indeed synaptic plasticity and cognitive functioning. Thus, specifically targeting
downstream proteins and pathways involved in excitotoxicity seems to be a more promising
approach. Such strategies are already being developed, such as the use of cell-permeable
peptides to disrupt the interaction of NR2B with PSD-95 and so uncouple NMDAR
activation from nNOS activation (Aarts and others 2002). Other promising approaches
include the specific targeting of the pro-death JNK signalling pathway, again with a cell-
permeable peptide (Borsello and others 2003).
The precise pathway, or pathways that mediate NMDAR-dependent cell death in ischemia
may depend on the neuronal subtype, the severity and duration of the episode, and the
position of the neuron within the lesion (infarct core or penumbra). Thus, it may be that
targeting JNK signalling or NO production may ameliorate neuronal loss in some scenarios,
but that blocking calpain or TRPM7 activation is more effective in others. Thus, a cocktail
of anti-death signalling drugs may be needed for an optimal effect. Moreover, their use,
where appropriate, in conjunction with the thrombolytic drug TPA (tissue plasminogen
activator) may aid in rapid drug delivery to the site of insult. In any case, the selective
targeting of multiple pro-death pathways downstream of the NMDARs may represent an
effective and better-tolerated therapeutic strategy than simple NMDAR blockade.
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Fig. 1. Pro-survival and-death signaling from the NMDA receptor (see text for details)
Note that pro-death signaling generally requires more intense activation of NMDARs than
pro-survival signalling. Also, the pathways marked with a * are favoured by extrasynaptic
NMDAR activation (Hardingham and others 2002; Ivanov and others 2006). ψm denotes
mitochondrial membrane potential.
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